Core Viewpoint - Koyuan Pharmaceutical announced the termination of its planned acquisition of 99.42% of Shandong Hongjitang Pharmaceutical Group Co., Ltd. due to changes in the overall market environment since the initial announcement of the transaction [1] Group 1: Transaction Details - The company initially intended to issue shares to 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd., to acquire the majority stake in Shandong Hongjitang [1] - Additionally, the company planned to issue shares to no more than 35 qualified specific investors to raise supporting funds [1] Group 2: Reasons for Termination - Koyuan Pharmaceutical stated that it has been actively organizing the transaction in accordance with relevant laws and regulations since the planning and initial announcement of the transaction [1] - The decision to terminate the restructuring was made after friendly consultations and thorough research with all relevant parties, based on a prudent consideration of the changes in the market environment [1]
科源制药终止重组事项